Elanco launches Befrena for dogs with allergic and atopic dermatitis: full analysis

Elanco has begun a phased U.S. launch of Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis, giving veterinarians another targeted option for managing chronic itch. The launch, announced May 18, 2026, follows USDA approval granted in December 2025 and extends Elanco’s push into companion animal dermatology after the earlier launch of Zenrelia. (prnewswire.com)

The move comes as dermatology remains a major commercial and clinical category in small animal practice. Itching is a common reason dogs are brought in for evaluation, and long-term management can be frustrating for clinicians, pet parents, and patients alike. In a recent dvm360 interview, Jennifer Miller, DVM, Elanco’s medical strategic lead for dermatology, described monoclonal antibodies as part of a broader wave of targeted therapies entering veterinary medicine, with Befrena representing the company’s latest step after its parvovirus antibody Trutect. (dvm360.com)

According to Elanco’s launch materials, Befrena is a caninized monoclonal antibody that neutralizes IL-31, a cytokine involved in transmitting itch signals. The company says the product starts controlling itch within 24 hours and provides relief for most dogs for 6 to 8 weeks after a single subcutaneous injection. It is administered in clinic by, or under the supervision of, a licensed veterinarian. Elanco also says the product has been shown to be safe and well tolerated in studies, with adverse events comparable to placebo, and notes that it has been used alongside immunotherapy, antipruritics, antimicrobials, and other common dermatology medications. The company also cautions that anti-drug antibodies may develop, as with other monoclonal antibodies, and says the product has not been tested in pregnant animals. (my.elanco.com)

Regulatory context matters here. Befrena is regulated by the USDA’s Center for Veterinary Biologics, not the FDA, because monoclonal antibody products like this fall within the veterinary biologics framework. USDA’s public licensing page notes that antibody products do not receive the same publicly posted product-summary data as some other biologics, which means outside observers may have less access to detailed licensing-study summaries than they would for certain vaccines or immunomodulators. That makes company disclosures, conference education, and future peer-reviewed publications especially important for clinicians trying to assess where Befrena fits in practice. (aphis.usda.gov)

Early expert commentary has been supportive, though it has largely come from company-associated channels so far. In Elanco’s launch release, veterinary dermatologist Tom Lewis, DVM, said his experience in clinical trials and the early experience program suggested Befrena was safe and effective, and that he expects it to become an important option for allergic dogs. In the dvm360 Q&A, Miller emphasized the unmet need for more itch-management tools and framed Befrena as part of a larger expansion of targeted veterinary therapeutics. Independent reaction from academic dermatologists or major professional bodies was limited in publicly indexed results at the time of writing. (prnewswire.com)

Why it matters: For practicing veterinarians, Befrena’s significance is less about novelty alone and more about optionality. Canine allergic and atopic dermatitis often require long-term, individualized treatment plans, and no single therapy works equally well for every patient. A new IL-31-targeting injectable with a labeled 6- to 8-week dosing interval could be useful for dogs that need consistent itch control, for pet parents who prefer in-clinic administration over daily oral dosing, or for cases where clinicians want to build a broader multimodal plan. At the same time, because this is entering a market with established dermatology therapies, uptake will likely depend on real-world duration of effect, pricing, clinic workflow, client acceptance, and how veterinarians perceive its place relative to other injectables and oral agents. (prnewswire.com)

Elanco’s broader strategy also helps explain the launch. In its 2025 annual report, the company highlighted Befrena as one of its key recent approvals and said it expected a second-quarter 2026 launch. That timing aligns with the current phased rollout and suggests the product is part of a larger effort to build depth in companion animal therapeutics, particularly in higher-value chronic care categories. (s1.q4cdn.com)

What to watch: The next signals to monitor are distribution breadth during the phased launch, any peer-reviewed efficacy and safety publications, conference presentations, and whether independent dermatologists begin sharing real-world experience on duration, repeat dosing, and case selection. Those details will likely determine whether Befrena becomes a niche alternative or a routine part of canine itch management in general and specialty practice. (prnewswire.com)